Exabis Library
Welcome to the e-CCO Library!
P494: A serum metabolite panel predicts Crohn’s disease relapse in patients discontinuing infliximab and continuing antimetabolite therapy: sub-analysis of the SPARE Trial.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P494: Can Patients Monitor Response To Ustekinumab In The Real World?
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P494: Impact of early optimization of ustekinumab on mid-term targets in severe Crohn's disease: THE MUST study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P494: Monocytic TNF production predicts response to infliximab treatment in Crohn’s disease but not ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P494: Multicentre cohort study to evaluate the need for re-intervention following multimodal treatment in Crohn's disease with perianal fistula
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P494: Phenotypic analysis revealed features of disease severity in familial versus sporadic cases of inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P494: Regional survey on satisfaction with healthcare in inflammatory bowel disease patients
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P495 Usefulness of a capsule endoscopy scoring system in understanding the disease state of Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P495: Biosimilar infliximab is effective and safe in inflammatory bowel disease patients naïve to anti-TNF therapy: a tertiary centre experience
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P495: Does drug level monitoring help us to understand the mechanism behind the superiority of combo therapy in inflammatory bowel diseases?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P495: Intensified infliximab rescue therapy for acute severe ulcerative colitis does not improve long term colectomy-free survival
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P495: Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P495: Spacing the administration interval of anti-TNF agents: a valid strategy for patients with inflammatory bowel disease?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P495: The interplay of biopsychosocial factors and quality of life in Inflammatory Bowel Diseases: a network analysis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P495: Vedolizumab trough concentrations and histological remission in Ulcerative Colitis: Results from the LOVE-UC study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P496 Feasibility and safety of single incision laparoscopic surgery for patients with complex Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P496: Adalimumab treatment reduces extraintestinal manifestations in patients with moderate-to-severe Crohn’s disease: a pooled analysis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P496: Antenatal thiopurine exposure in women with IBD is associated with intrahepatic cholestasis of pregnancy
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P496: Efficacy and safety of elective switching of inflammatory bowel disease patients from intravenous to subcutaneous infliximab (IFX): a multi-centre cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P496: Efficacy and safety of ustekinumab for chronic antibiotic refractory pouchitis: A Belgian open-label multicentre pilot study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM